Breast surgery in the 'Arimidex, tamoxifen alone or in combination' (ATAC) trial - American women are more likely than women from the United Kingdom to undergo mastectomy

被引:28
|
作者
Locker, GY
Sainsbury, JR
Cuzick, J
机构
[1] Northwestern Univ, Evanston NW Healthcare, Evanston, IL 60201 USA
[2] UCL, Dept Surg, London, England
[3] Wolfson Inst Prevent Med, Canc Res UK, London, England
关键词
anastrozole; tamoxifen; adjuvant; breast carcinoma; mastectomy;
D O I
10.1002/cncr.20435
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Various factors affect patients' decisions regarding whether to undergo surgery for the treatment of early-stage breast carcinoma. The 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial, the largest multinational randomized trial of adjuvant therapy for patients with operable breast carcinoma to date, offers the opportunity to investigate whether nationality is one such factor. METHODS. After receiving primary therapy for early-stage breast carcinoma, 9366 women (from a total of 21 countries) were randomized to receive anastrozole, tamoxifen, or anastrozole plus tamoxifen for 5 years. In the current study, mastectomy and breast conservation rates were compared among participating countries. The possibility that variations from country to country could be explained by inequalities in terms of pathologic, clinical, and hospital-related correlates of surgical choice was explored first on univariate analysis and then on multivariate logistic analysis. RESULTS. National mastectomy rates ranged from 20% to 97%; 51% of the 2222 enrollees from the United States had undergone mastectomy, compared with 42% of the 3228 enrollees from the United Kingdom (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.28-1.60; P < 0.001). On univariate analysis, larger tumor size, positive lymph node status, higher tumor grade, older age, and adjuvant chemotherapy use were found to be correlated with mastectomy use. In contrast, positive hormone receptor status, increased body weight, and enrollment at a center that had more than 40 enrollees were found to be associated with breast conservation. The same correlates were identified on multivariate logistic analysis (P < 0.05), except that the number of enrollees at a patient's treatment center no longer possessed predictive value. After correction for these correlated factors, residence in the United States (compared with residence in the United Kingdom) remained an independent predictor of mastectomy use (OR, 1.44; 95% Cl, 1.26-1.64; P < 0.001). CONCLUSIONS. American women enrolled in the ATAC trial were more likely to undergo aggressive surgery compared with their counterparts from the United Kingdom. More generally, nationality was found to be an independent determinant of surgical choice in the current study. Cancer 2004;101:735-40. (C) 2004 American Cancer Society.
引用
收藏
页码:735 / 740
页数:6
相关论文
共 50 条
  • [1] Breast surgery in the ATAC trial: women from the United States are more likely to have mastectomy.
    Locker, G
    Sainsbury, R
    Cuzick, J
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S35 - S35
  • [2] The ATAC ('Arimidex' Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PMI) women
    Tobias, JS
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S92 - S92
  • [4] Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
    Fallowfield, L
    Cella, D
    Cuzick, L
    Francis, S
    Locker, G
    Howell, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) : 4261 - 4271
  • [5] Maturity of data from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial
    Bianco, A. R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 99 - 99
  • [6] Anastrozole is superior to tamoxifen in the treatment of postmenopausal women with early breast cancer - first results of the ATAC ('Arimidex', Tamoxifen, alone or in combination) trial
    Sainsbury, R
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 137 - 137
  • [7] ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial-anastrozole is superior to tamoxifen as adjuvant treatment in postmenopausal women with early breast cancer.
    Bianco, R
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S155 - S155
  • [8] Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
    Houghton, J
    Baum, M
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S83 - S83
  • [9] Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
    Baum, M
    Houghton, J
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S39 - S39
  • [10] Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women:: a sub-protocol of the 'Arimidex™ and Tamoxifen Alone or in Combination' (ATAC) trial
    Baum, M
    Dowsett, M
    Coibion, M
    Bianco, AR
    Cuzick, J
    George, WD
    Gray, J
    Howell, A
    Houghton, J
    Williams, N
    Sloane, J
    Tobias, J
    Buzdar, A
    Anderson, MD
    Jackson, I
    Sahmoud, T
    Gallagher, J
    Webster, A
    Gangji, D
    Petrakova, K
    Konopasek, B
    Mares, P
    Vodvarka, P
    Alcazar, A
    Campos, O
    Maxwell, A
    Goedhals
    Hacking, D
    Landers, G
    Smith, L
    Vorobiof, DA
    Werner, ID
    Blamey, R
    Coleman, R
    Grieve, RJ
    Hickish, T
    Howell, A
    Nicholls, JC
    Nicholson, S
    Raymond, S
    Salman, A
    Blum, J
    Clark, R
    Lyss, A
    Miletello, G
    Sternberg, J
    Forbes, J
    Coibion, M
    Nabholtz, JM
    Guastalla, JP
    BRITISH JOURNAL OF CANCER, 2001, 85 (03) : 317 - 324